glp 1 drugs novo nordisk EMA will monitor suicide risk in Nordisk's GLP-1 products GLP-1 RA education

Your primary care provider or a specialist can help you weigh the pros and cons of GLP-1s

Conclusion The clinical and research data accumulated up to July 2026 confirms that GLP-1 receptor agonists possess a highly favorable safety and tolerability profile, especially when weighed against the profound metabolic and cardiovascular benefits they offer

Safety concerns include gastrointestinal issues, potential aspiration risk, and rare anaphylactic reactions

Of these articles, one was an open-label study ( 3.3 Summary of Outcomes 3.3.1 Efficacy Outcomes 3.3.1.1 HbA1c Overall, all 8 articles (Zinman et al., 2019

their association with SGLT-2 inhibitors requires further confirmation through large, randomized trials ( SGLT2 inhibitors should be discontinued in specific clinical scenarios to mitigate potential adverse events